Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902991 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17581833 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL13436631 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL14012280 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23998665 | 0.97 | CTSS (0.51) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23106074 | 0.92 | CTSK (0.50) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL29593613 | 0.91 | CTSK (0.53) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL25459969 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17209941 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL28342732 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-11000598-B2 | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | ZYMEWORKS INC. (CA) | 2021-05-11 | — | — | US | disclosed |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2528625-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2013-07-10 | — | — | EP | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2011130598-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | CTSS 1738/4885CTSK 1647/4885MEN1 843/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | CTSS 4451/4885CTSK 4316/4885MEN1 4139/4885 |
| US-11000598-B2 | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | ERBB2, FCGR2A, FCER2 | CTSS 1033/4885CTSK 1392/4885MEN1 3757/4885 |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | CTSS 1077/4885CTSK 1012/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.